298 related articles for article (PubMed ID: 26724568)
1. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality.
Anderberg RH; Richard JE; Hansson C; Nissbrandt H; Bergquist F; Skibicka KP
Psychoneuroendocrinology; 2016 Mar; 65():54-66. PubMed ID: 26724568
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-Like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight.
Anderberg RH; Richard JE; Eerola K; López-Ferreras L; Banke E; Hansson C; Nissbrandt H; Berqquist F; Gribble FM; Reimann F; Wernstedt Asterholm I; Lamy CM; Skibicka KP
Diabetes; 2017 Apr; 66(4):1062-1073. PubMed ID: 28057699
[TBL] [Abstract][Full Text] [Related]
3. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats.
Rodriquez de Fonseca F; Navarro M; Alvarez E; Roncero I; Chowen JA; Maestre O; Gómez R; Muñoz RM; Eng J; Blázquez E
Metabolism; 2000 Jun; 49(6):709-17. PubMed ID: 10877194
[TBL] [Abstract][Full Text] [Related]
4. Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior.
Anderberg RH; Anefors C; Bergquist F; Nissbrandt H; Skibicka KP
Physiol Behav; 2014 Sep; 136():135-44. PubMed ID: 24560840
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
6. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.
Kanoski SE; Fortin SM; Arnold M; Grill HJ; Hayes MR
Endocrinology; 2011 Aug; 152(8):3103-12. PubMed ID: 21693680
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.
van Bloemendaal L; IJzerman RG; Ten Kulve JS; Barkhof F; Konrad RJ; Drent ML; Veltman DJ; Diamant M
Diabetes; 2014 Dec; 63(12):4186-96. PubMed ID: 25071023
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.
McKay NJ; Kanoski SE; Hayes MR; Daniels D
Am J Physiol Regul Integr Comp Physiol; 2011 Dec; 301(6):R1755-64. PubMed ID: 21975647
[TBL] [Abstract][Full Text] [Related]
9. Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats.
Barrera JG; D'Alessio DA; Drucker DJ; Woods SC; Seeley RJ
Diabetes; 2009 Dec; 58(12):2820-7. PubMed ID: 19741167
[TBL] [Abstract][Full Text] [Related]
10. Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner.
Zhao S; Kanoski SE; Yan J; Grill HJ; Hayes MR
Int J Obes (Lond); 2012 Dec; 36(12):1522-8. PubMed ID: 22249232
[TBL] [Abstract][Full Text] [Related]
11. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.
Smith GC; Vickers MH; Cognard E; Shepherd PR
Schizophr Res; 2009 Nov; 115(1):30-40. PubMed ID: 19679451
[TBL] [Abstract][Full Text] [Related]
12. Combined stimulation of glucagon-like peptide-1 receptor and inhibition of cannabinoid CB1 receptor act synergistically to reduce food intake and body weight in the rat.
Bojanowska E; Radziszewska E
J Physiol Pharmacol; 2011 Aug; 62(4):395-402. PubMed ID: 22100840
[TBL] [Abstract][Full Text] [Related]
13. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
14. Role of lateral septum glucagon-like peptide 1 receptors in food intake.
Terrill SJ; Jackson CM; Greene HE; Lilly N; Maske CB; Vallejo S; Williams DL
Am J Physiol Regul Integr Comp Physiol; 2016 Jul; 311(1):R124-32. PubMed ID: 27194565
[TBL] [Abstract][Full Text] [Related]
15. Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans.
van Bloemendaal L; Veltman DJ; Ten Kulve JS; Groot PF; Ruhé HG; Barkhof F; Sloan JH; Diamant M; Ijzerman RG
Diabetes Obes Metab; 2015 Sep; 17(9):878-86. PubMed ID: 26094857
[TBL] [Abstract][Full Text] [Related]
16. Effects of centrally-injected glucagon-like peptide-1 on pilocarpine-induced seizures, anxiety and locomotor and exploratory activity in rat.
Gulec G; Isbil-Buyukcoskun N; Kahveci N
Neuropeptides; 2010 Aug; 44(4):285-91. PubMed ID: 20227110
[TBL] [Abstract][Full Text] [Related]
17. Exogenous glucagon-like peptide-1 acts in sites supplied by the cranial mesenteric artery to reduce meal size and prolong the intermeal interval in rats.
Williams KE; Washington MC; Johnson-Rouse T; Johnson RE; Freeman C; Reed C; Heath J; Sayegh AI
Appetite; 2016 Jan; 96():254-259. PubMed ID: 26431682
[TBL] [Abstract][Full Text] [Related]
18. Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.
Evers A; Haack T; Lorenz M; Bossart M; Elvert R; Henkel B; Stengelin S; Kurz M; Glien M; Dudda A; Lorenz K; Kadereit D; Wagner M
J Med Chem; 2017 May; 60(10):4293-4303. PubMed ID: 28448133
[TBL] [Abstract][Full Text] [Related]
19. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
Baggio LL; Huang Q; Cao X; Drucker DJ
Gastroenterology; 2008 Apr; 134(4):1137-47. PubMed ID: 18313669
[TBL] [Abstract][Full Text] [Related]
20. Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats.
Reidelberger RD; Haver AC; Apenteng BA; Anders KL; Steenson SM
Obesity (Silver Spring); 2011 Jan; 19(1):121-7. PubMed ID: 20559304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
